This study tests a one-time treatment called BEAM-101 for people with severe sickle cell disease. It uses the patient's own blood stem cells, which are gene-edited to produce healthy red blood cells. The goal is to reduce or eliminate painful vaso-occlusive crises. The trial invo…
Phase: PHASE1, PHASE2 • Sponsor: Beam Therapeutics Inc. • Aim: Disease control
Last updated May 02, 2026 07:10 UTC